Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks

This study has been terminated.

(Study terminated due to inadequate recruitment)

Sponsor:

Information provided by:

Thomas Jefferson University

ClinicalTrials.gov Identifier:

NCT00329732

First received: May 24, 2006

Last updated: July 21, 2011

Last verified: July 2011

History of Changes

Results First Received: May 24, 2011

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Investigator); Primary Purpose: Treatment
Condition:	Migraine
Interventions:	Drug: 0.5% bupivicaine and 2% lidocaine Drug: Saline placebo

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Lidocaine/Bupivicaine	No text entered.
Saline (Placebo)	No text entered.

Participant Flow: Overall Study

	Lidocaine/Bupivicaine	Saline (Placebo)
STARTED	2	0
COMPLETED	2	0
NOT COMPLETED	0	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Lidocaine/Bupivicaine	No text entered.
Saline (Placebo)	No text entered.
Total	Total of all reporting groups

Baseline Measures

	Lidocaine/Bupivicaine	Saline (Placebo)	Total
Number of Participants [units: participants]	2	0	2
Age [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	2	0	2
>=65 years	0	0	0
Gender [units: participants]
Female	2	0	2
Male	0	0	0
Region of Enrollment [units: participants]
United States	2	0	2

Outcome Measures

1. Primary:

Percentage of Patients Experiencing Significant Change on a 4 Point Pain Scale at 30 Minutes Post-injection, Active Drug Versus Placebo. Significant Change is Defined as a Change on the 4 Point Pain Scale From Moderate or Severe to Mild. No Pain Equals 0. [ Time Frame: 30 minutes ]

Show Outcome Measure 1

2. Secondary:

Secondary Measures Include:Percentage of Subjects Achieving a Significant Change on a 10 Point Pain Scale at 30 Minutes Post-injection, Active Drug Versus Placebo; [ Time Frame: 30 minutes ]

Results not yet posted. Anticipated Posting Date: No text entered. Safety Issue: No

3. Secondary:

Percentage of Subjects Achieving a Significant Change on a 100mm Visual Analogue Scale (VAS) at 30 Minutes Post-injection, Active Drug Versus Placebo. Significant Change is Defined as a Greater Than or Equal to 2cm Change. [ Time Frame: 30 minutes ]

Results not yet posted. Anticipated Posting Date: No text entered. Safety Issue: No

4. Secondary:

Percentage of Subjects Achieving Resolution of Associated Symptoms of Nausea, Vomiting, Photophobia, Phonophobia, Osmophobia, Allodynia Measured During the First 30 Minutes Post-injection, Active Drug Versus Placebo; [ Time Frame: 30 minutes ]

Results not yet posted. Anticipated Posting Date: No text entered. Safety Issue: No

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Kathleen Bradley
Organization: Thomas Jefferson University
phone: 215-955-2025
e-mail: Kathleen.Bradley@jefferson.edu

No publications provided

Responsible Party:	Bruce Smith, Thomas Jefferson University
ClinicalTrials.gov Identifier:	NCT00329732 History of Changes
Other Study ID Numbers:	GON-DBPC/WBY
Study First Received:	May 24, 2006
Results First Received:	May 24, 2011
Last Updated:	July 21, 2011
Health Authority:	United States: Institutional Review Board

To Top